Moleculin Biotech, Inc.
MBRXMoleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing oncology drugs and treatments for difficult-to-treat cancers. The company specializes in the research and development of small molecule therapeutics targeting cancer metabolism, tumor microenvironment, and resistant cancer cells. Moleculin's pipeline includes compounds designed for oral administration, aiming to address unmet medical needs in oncology.
Company News
Over 100 pharmaceutical companies are actively developing 150+ pipeline drugs for Acute Myeloid Leukemia (AML), with approximately 10 drugs in late-stage development and 50+ in mid and early stages, focusing on targeted therapies and personalized treatment approaches.
Moleculin reported positive results from a Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases. The trial showed improved overall survival and progression-free survival, with a clinical benefit rate of 59.4%.
Moleculin Biotech, a late-stage pharmaceutical company, presented its top five reasons for why investors should pay attention to the company in 2025, including updates on its lead drug candidate Annamycin and other pipeline programs.
Moleculin Biotech, Inc. announced that its abstract has been accepted for poster presentation at the Acute Leukemias XIX (ISALXIX) International Symposium. The abstract focuses on the company's drug candidate Annamycin, which is in development for the treatment of relapsed or refractory acute myeloid leukemia (AML).
Moleculin Biotech, a late-stage pharmaceutical company, announced that its CEO Walter Klemp participated in a Virtual Investor segment to discuss the progress of the company's Phase 3 pivotal trial evaluating Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML) patients.
